AstraZeneca reinforces target of $45 billion revenues by 2023

Anglo-Swedish pharma major AstraZeneca (LSE: ANZ) today provided an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth.

The firm’s chief executive Pascal Soriot said: “I am delighted with the progress we are making on our strategy….We have more than doubled the number of potential medicines in our late-stage pipeline since 2012 and we are on track to return to growth by 2017. Fuelled by a very exciting portfolio of new products, oncology is set to become AstraZeneca’s sixth growth platform and play a large part in supporting our efforts to bring life-changing medicines to patients as well as delivering long-term growth. We are building a sustainable, more durable and profitable company. The tangible results being delivered reinforce our confidence that we will achieve our target of delivering revenues of over $45 billion by 2023.”

Robust financials and disciplined capital allocation are delivering shareholder value